CBD and acne: from sebum in the lab to a 368-patient trial

The reference study was published in 2014 in the Journal of Clinical Investigation by Oláh and colleagues. The team worked on a human sebocyte line (SZ95) and on whole human skin kept in culture. They first stimulated lipid production with “pro-acne” agents, then added CBD. CBD brought this abnormally high lipogenesis back to normal, slowed cell multiplication without killing the cells and reduced the expression of several inflammatory mediators.

This remains a laboratory result. Cultured cells and donated skin reproduce neither the length of a treatment, nor the way a product crosses the skin barrier, nor the other factors in acne. The result justifies human trials. It says nothing about what a cream does.

You often read that sebocytes “carry CB1 and CB2 receptors”. That is inaccurate. A study published in 2008 in the FASEB Journal showed that SZ95 sebocytes express the CB2 receptor but not CB1. In these cells, the endocannabinoids made by the body increase lipid production through CB2.

CBD does not act through that route. In the 2014 study, blocking CB1 and CB2 did not prevent its effect. The authors attribute it to two other targets: the TRPV4 ion channel for the effect on lipids, and the adenosine A2a receptor for the anti-inflammatory effect they observed. These mechanisms were described in cells. They say nothing about what happens on a face.

The most direct test is a controlled trial. The BTX 1503 phase 2 trial, registered on ClinicalTrials.gov as NCT03573518, enrolled 368 people aged 12 to 40 with moderate to severe facial acne. They were split into four groups of 92: 5% CBD solution twice a day, 5% CBD once a day, 2.5% CBD once a day, and vehicle, meaning the same solution without CBD. The trial ended in September 2019; its results were posted on 18 April 2022.

Every group improved, vehicle included. That is exactly why a trial has a vehicle group: what counts is the gap between the product and the same formula without CBD. That gap is at most 0.7 lesion in favour of CBD, with a standard deviation of about 12.6 lesions in each group. The highest-dose group even did slightly worse than the vehicle. On this measure, the trial shows no benefit from CBD.

A cosmetic is not a medicine, and its CBD content has a safety limit. The European Scientific Committee on Consumer Safety (SCCS) published its opinion SCCS/1685/25 on 24 April 2026. It considers CBD safe up to 0.19% in cosmetics applied to the skin or used in the mouth, and THC present as an impurity up to 0.00025%. The opinion excludes products that can be inhaled, such as sprays, and the committee notes that the data submitted were limited.

The comparison speaks for itself. The BTX 1503 trial used 2.5% and 5% CBD, 13 to 26 times that ceiling. A cosmetic cream sold in France contains, at most, a fraction of the dose that did no better than the vehicle. On the label, CBD appears in the INCI list as “cannabidiol”; its concentration does not have to be stated. Our guide to assessing a CBD cream, balm or gel shows how to read the rest of the label.

Three texts set the line. Regulation (EC) No 1223/2009 forbids, in its Article 20, the use of text, names, trade marks or pictures to attribute to a cosmetic characteristics or functions it does not have. Regulation (EU) No 655/2013 sets six criteria for any claim: legal compliance, truthfulness, evidential support, honesty, fairness and informed decision-making.

The third text moves the boundary. Under Article L5111-1 of the French Public Health Code, any substance “presented as having curative or preventive properties with regard to human diseases” is a medicine. Acne vulgaris is a skin disease: a product presented as “anti-acne” or “clears spots” leaves the cosmetic field. On top of that comes a rule specific to CBD: the MILDECA points out that products containing CBD may not make any therapeutic claim, on pain of criminal penalties.

Our article on permitted claims for CBD cosmetics goes through the six criteria one by one.

Acne that scars, spreads or lasts is a matter for a doctor or dermatologist. Topical and oral prescription treatments exist. No CBD medicine is authorised for acne: the only cannabidiol-based medicine authorised in France, Epidyolex, is reserved for certain rare forms of epilepsy.

A CBD cosmetic remains a care and comfort product. Choose it for its texture, how your skin tolerates it and its ingredient list, not for an effect on acne. The same caution applies to other reactive skin, as our article on CBD, eczema and psoriasis explains.